New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
06:04 EDTAZN, WFMStocks with implied volatility below IV index mean; WFM AZN
Stocks with implied volatility below IV index mean; Whole Foods (WFM) 28, AstraZeneca (AZN) 22 according to iVolatility.
News For AZN;WFM From The Last 14 Days
Check below for free stories on AZN;WFM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 31, 2014
06:01 EDTWFMWhole Foods implied volatility of 45 at upper end of index mean range
Subscribe for More Information
July 30, 2014
18:54 EDTWFMOn The Fly: After Hours Movers
UP AFTER EARNINGS: VistaPrint (VPRT), up 20.6% after reporting better than expected quarterly results and guiding fiscal 2015 higher than analyst estimates... Mobileiron (MOBL), up 16.5%... LivePerson (LPSN), up 10.6%... Equinix (EQIX), up 1.1%... Whiting Petroleum (WLL), up 1.2%. DOWN AFTER EARNINGS: Glu Mobile (GLUU), down 9.9% after reporting second quarter results and that it will acquire Cie Games for $100M in cash and stock... ServiceNow (NOW), down 5.8%... Akamai (AKAM), down 5.3%... Westell Technologies (WSTL), down 7.5%... Solazyme (SZYM), down 4%... Whole Foods (WFM), down 3.4% after reporting third quarter results and guidance for the fourth quarter and fiscal 2014... Kraft Foods (KRFT), down 1.6%... Lam Research (LRCX), down 1.6%... Yelp (YELP), reverses in after-hours trading and shares are down marginally after reporting a decline in newly added businesses. ALSO LOWER: Penn Virginia (PVA), down 2.1% after announcing that it has sold Eagle Ford Shale acreage rights for $150M... Yum! Brands (YUM), down 5.6% after saying that OSI had a "significant, negative impact" to its sales in China.
16:12 EDTWFMWhole Foods sees Q4 EPS 31c-33c, consensus 34c
Subscribe for More Information
16:09 EDTWFMWhole Foods down 7% after lowering FY14 outlook
16:08 EDTWFMWhole Foods narrows FY14 EPS view to $1.52-$1.54 from $1.52-$1.56
FY14 consensus $1.53. Lowers FY14 sales growth view to 9.6%-9.9% from prior 10.5%-$11%. FY14 revenue consensus $14.28B. Lowers FY14 comparable sales growth view to 4.1%-4.4% from 5.0%-5.5%. Lowers FY14 number of expected new stores to 38 from 36-39. Lowers FY14 CapEx view to $725M-$750M from $675-$725M.
16:06 EDTWFMWhole Foods drops after earnings report, levels to watch
Subscribe for More Information
16:04 EDTWFMWhole Foods announces new $1B share repurchase plan
Subscribe for More Information
16:03 EDTWFMWhole Foods reports Q3 EPS 41c, consensus 39c
Reports Q3 revenue $3.4B, consensus $3.39B. Reports Q3 comparable store sales increased 3.9%.
16:00 EDTWFMOptions Update; July 30, 2014
Subscribe for More Information
15:31 EDTWFMNotable companies reporting after market close
Subscribe for More Information
12:56 EDTWFMWhole Foods Markets August weekly volatility elevated into Q3
theflyonthewall.com: Whole Foods Markets August weekly volatility elevated into Q3 Whole Foods Markets August weekly call option implied volatility is at 99, August is at 44, November and January is at 29; compared to its 26-week average of 33 according to Track Data, suggesting larger near term price movement into the expected release of Q3 results after the market close on July 30. :theflyonthewall
06:10 EDTAZNAstraZeneca enters respiratory disease transaction with Almirall
AstraZeneca announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875M on completion, and up to $1.22B in development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments. Upon completion of the transaction, AstraZeneca will own the rights for the development and commercialization of Almirall’s existing proprietary respiratory business, including rights to revenues from Almirall’s existing partnerships, as well as its pipeline of investigational novel therapies. The franchise includes Eklira, LAS40464, LAS100977 or abediterol, and multiple pre-clinical programs. Under the agreement, Almirall Sofotec, an Almirall subsidiary focused on the development of innovative proprietary devices, will also transfer to AstraZeneca. Almirall’s pipeline of respiratory assets and its device capabilities further strengthen AstraZeneca’s respiratory portfolio, which includes Symbicort and Pulmicort, as well as the company’s investigational medicines in development. The addition of aclidinium and the combination of aclidinium with formoterol, both in proprietary Genuair device, will allow AstraZeneca to offer patients a choice between dry powder inhaler and metered dose inhaler devices across a range of molecules and combinations. AstraZeneca and Almirall anticipate that, subject to local consultation and legislation, a significant number of employees dedicated to the respiratory business, including Almirall Sofotec employees, will transfer to AstraZeneca. The transaction is subject to certain competition law clearances as well as other customary terms and conditions. The companies anticipate the transaction will complete by the end of 2014.Reference Link
July 29, 2014
05:56 EDTWFM Stocks with implied volatility movement; WFM MU
Stocks with implied volatility movement; Whole Foods (WFM) 46, Micron (MU) 38 according to iVolatility.
July 28, 2014
07:30 EDTWFMWhole Foods Markets August weekly volatility elevated into Q3
Whole Foods Markets August weekly call option implied volatility is at 99, August is at 44, November and January is at 29; compared to its 26-week average of 33 according to Track Data, suggesting larger near term price movement into the expected release of Q3 results after the market close on July 30.
05:36 EDTAZNQIAGEN, AstraZeneca announce collaboration
QIAGEN (QGEN) announced a collaboration agreement with AstraZeneca (AZN) for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AstraZeneca's targeted therapy for non-small cell lung cancer, or NSCLC. The project builds on a master framework agreement signed by both companies in 2013 and aims to develop and market a novel QIAGEN companion diagnostic that analyzes plasma samples to assess EGFR mutation status in NSCLC patients. The assay will be designed to guide the treatment of NSCLC patients with Astra Zeneca's oral monotherapy anti-cancer treatment when tumor tissue is not available. QIAGEN already offers the therascreen EGFR RGQ PCR Kit as a tissue-based companion diagnostic for lung cancer patients, which was approved in the U.S. by the FDA in July 2013 and in China in May 2014. The companies will collaborate to create a new companion diagnostic for IRESSA based on liquid biopsy samples from NSCLC patients, rather than requiring invasive surgical collection of tissue samples. Data from several studies, including the IFUM Study presented at the "World Lung 2013" conference, provided evidence of the ability to assess the EGFR status of advanced lung cancer patients using blood / plasma samples. This breakthrough provides hope for patients for whom surgical biopsy is not an option by enabling them to have their EGFR mutation status assessed using a less invasive method.
July 22, 2014
10:00 EDTWFMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:35 EDTWFMWhole Foods downgraded to Underperform from Peer Perform at Wolfe Research
Wolfe Research downgraded Whole Foods to Underperform based on checks that indicate increased promotions and weaker sales trends.
08:21 EDTWFMWhole Foods continues to have share gain opportunities, says Morgan Stanley
Morgan Stanley believes Whole Foods can continue to grow its share within the natural/organic market to 29% in 2018 from 24% in 2013. The firm said Whole Foods benefits from its leading position and sees upside potential to estimates. Shares are Overweight rated with a $50 price target.
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
06:15 EDTWFMWhole Foods implied volatility of 43 at upper end of index mean range
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use